← All trials
NCT03314662
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 17, 2017
- Primary completion
- Dec 11, 2017
- Completion date
- May 17, 2018
- First posted
- —
- Last posted
- —
- Enrollment
- 1778
- Arms / groups
- 3 / —
- Source
- AACT · ingestion pipeline
Sponsors
- CSL BehringLead sponsor
- CSL BehringStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.